STK11 and non-small cell lung carcinoma: Furthermore, multiple studies have demonstrated that STK11/KEAP1 mutations in NSCLC contribute to the establishment of an immunosuppressive TME, ultimately resulting in primary resistance to αPD-1 therapy (81–86).